Corcept Therapeutics Inventory Jumps On Upbeat Ovarian Most cancers Trial Knowledge, Analysts Increase Value Forecast – Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics Included CORT introduced on Monday that the ROSELLA Section 3 trial of relacorilant plus nab-paclitaxel in sufferers with platinum-resistant ovarian most cancers met its main endpoint of improved progression-free survival, as assessed by blinded impartial central evaluate (PFS-BICR).

In ROSELLA, sufferers handled with relacorilant and nab-paclitaxel chemotherapy skilled a 30% discount within the threat of illness development in comparison with sufferers handled with nab-paclitaxel alone.

Additionally Learn: Corcept Therapeutics’ FDA-Accredited Korlym Hits Most important Aim In Cushing’s Syndrome Sufferers With Troublesome-To-Management Diabetes

The median PFS-BICR was 6.5 months, in comparison with 5.5 months in sufferers who obtained nab-paclitaxel alone.

At an interim analysis of general survival (OS), sufferers handled with relacorilant plus nab-paclitaxel had a big enchancment in OS, with a median OS of 16.0 months, in comparison with 11.5 months for sufferers receiving nab-paclitaxel alone.

Relacorilant was well-tolerated and no new security indicators have been noticed.

The entire outcomes of ROSELLA might be introduced at a medical convention this yr.

The ROSELLA trial enrolled 381 sufferers with platinum-resistant ovarian most cancers.

Analyst Response:

• HC Wainwright maintains Corcept Therapeutics with a Purchase, elevating the worth goal from $115 to $150.
• Truist Securities maintains Corcept Therapeutics with a Purchase, elevating the worth goal from $76 to $150.

Value Motion: CORT is up 85.6% at $101.80 on the final test on Monday.

Learn Subsequent:

Picture: Shutterstock